Creating neurotransformational medicines is our priority

We believe patients suffering from debilitating headache disorders and difficult-to-treat psychiatric disorders, like OCD, no longer have to live this way

People with severe headaches deal with disabling pain that keeps them from working and participating in everyday life. OCD sufferers, although not suffering from pain, are also limited in their ability to lead regular lives and often experience psychological despair.

Both groups agonize due to few medical alternatives, making them feel hopeless as their medical needs continue to be unmet. In addition, they carry the burden of their isolation and miss out on raising their children and being with family and community. They also feel different and separate from others because of their disorder and are often viewed as “freaks” in severe cases or “making it up” in more mild ones.

For too long, they have been poorly understood and under-served.

At Ceruvia Lifesciences, we get it and are doing something about it.

We seek opportunities to create neurotransformational medical breakthroughs for these two disorders, amongst many, with our products.

Since 2017, Ceruvia Lifesciences, founded by Carey Turnbull, has relentlessly focused on the discovery, development, and commercialization of transformational medicines to deliver meaningful relief to patients suffering from these hard-to-treat headache disorders and OCD.

Seeking opportunities to create new transformational medical breakthroughs

Invest icon


Create significant health impact by providing targeted funding that focuses on providing relief to marginalized sufferers and ultimately making a difference in millions of people’s lives.

We fill a significant gap in the psychedelic and related drug industry (>$1.2bn/annum) that current organizations do not pursue, positioning us as leaders in this space.

Provide Evidence

Continue to generate data from controlled clinical trials in academic settings at leading institutions.

We fund and work with innovative collaborators and partners to discover and develop promising medicines to treat challenging disorders.

Ceruvia Lifesciences is built on sound science and has gathered key, experienced consultants and scientific advisors to advance projects.

Prove icon
Advance icon


We are the world’s first producers of GMP LSD, which we supply free of cost to academic research sites, and GMP BOL-148.

We adhere to the highest development, testing, and manufacturing standards as established by regulatory authorities as well as pharmaceutical industry associations and organizations.


We envision a future where Ceruvia Lifesciences can deploy treatments to create a significant benefit for all stakeholders in our focus areas: patients, caregivers, payers, and health care providers.

Commercialize icon

Carey Turnbull

A Word from Our Founder & CEO



Ceruvia Lifesciences’ project is to make psilocybin, and related compounds approved medications for headache disorders.

As such, we promote medical research on cluster headache and migraine, working closely with the patient advocacy group Clusterbusters, a knowledgeable advisor we admire for their years of hard work, expertise, and advice. But with the proviso, Ceruvia cannot encourage the use of psilocybin outside of an approved and regulated medical setting.

We hope to add value to that community and ease its suffering within that context.


Meet Our Veteran Team


Carey Turnbull

Founder/ CEO

10+ years Investment/ Philanthropy in Psychedelic Medicine


Kathleen Monroe


20+ years Pharmaceutical Project Management


Judy Ashworth, MD

Clinical & Regulatory Strategy

20+ years Analgesic & CNS Drug Development


Jeanne Bonelle


40+ years Quality Assurance & CMC Development


Shayne Gad, PhD, DABT

Pharmacology & Toxicology

40+ years Toxicology & Pharmacology


Silvia Dickhut

Global Project Lead

20+ years Drug Development


Sophie Goubet Sieradzki

Clinical Research Associate (OCD)

15+ years Clinical Research


Tom Huijbers

Regulatory Affairs, R&D

20+ years Regulatory Pharmaceutical Strategist


Ryan Lanier, PhD

Clinical Scientist

20+ years Pre-Clinical & Clinical Development of CNS Drugs


Stephan Loose, MBA

Business Development

15+ years Pharmaceutical Commercialization & Business Development


Amy Poshusta, PhD

Non-clinical Development

20+ years Pharmaceutical Drug Development


John Wetzel, PhD


30+ years Pharmaceutical Drug Development & CMC

Scientific Advisors


Professor, Department of Psychiatry at NYU Grossman School of Medicine, Addiction & Social Anxiety Disorders

Michael Bogenschutz, MD

NYU Langone’s Department of Psychiatry


Professor of Psychiatry at Yale University School of Medicine

Clinical Director & Psychiatrist at VA Connecticut Healthcare System

Director, VA-Yale Schizophrenia Research Fellowship program

Director, Schizophrenia Neuropharmacology Research Group at Yale (SNRGY)

Deepak D’Souza, MBBS, MD

Yale University School of Medicine

Yale School of Medicine logo

Assistant Professor of Clinical Neurology

Chief, Division of General Neurology, Neurology

Director, Fellowship Program, Headache & Facial Pain Center

Christoph Gottschalk, MD, FAHS

Yale University School of Medicine

Yale School of Medicine logo
Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates

Adjunct Professor, Behavioral Biology, Medical School’s Department of Psychiatry and Behavioral Sciences

Jack Henningfield, PhD

Regulatory Strategy

 Founder, Council on Spiritual Practices

Bob Jesse



Assistant Professor of Psychiatry, Yale University School of Medicine

Ben Kelmendi, MD

Yale University School of Medicine

Yale School of Medicine logo

Distinguished Professor Emeritus, Purdue University

Former Robert C. and Charlotte P. Anderson Distinguished Chair of Pharmacology

Adjunct Professor, Chemical Biology and Medicinal Chemistry, UNC Chapel Hill

Founding President Heffter Research Institute

Dave Nichols, PhD

UNC Eschelman School of Pharmacy

Carolina Pharmacy seal logo

Professor of Psychiatry and Psychotherapy – Hannover Medical School, Germany

Visiting Professor (2012-2015) – Harvard Medical School, MA, USA

Torsten Passie, PhD

Hannover Medical School

Hannover Medical School

Professor of Psychiatry

Assistant Chair for Translational Research, Psychiatry

Director, Yale OCD Research Clinic

Director, Neuroscience Research Training Program, Yale Department of Psychiatry

Chris Pittenger, MD, PhD, FAPA, FANA

Yale University School of Medicine

Yale School of Medicine logo

Assistant Professor of Neurology, Yale School of Medicine

Medical Director, Headache Center of Excellence, VA Connecticut Healthcare System

Emmanuelle Schindler, MD, PhD

Yale University School of Medicine

Yale School of Medicine logo

Founder and President – Clusterbusters, Inc.

Board of Directors – AHDA (Alliance for Headache Disorder Advocacy)

Bob Wold


Clusterbusters logo

Professor of Neurology and Co-Director Inpatient Program, Jefferson University Hospital

Founder, Physician & Advisor Coalition for Headache and Migraine Patients (CHAMP)

William Young, MD

Jefferson University Hospital

Jefferson University and Hospitals logo

Meet Our Collaborators and Partnerships

Usona Institute is a non-profit medical research organization dedicated to supporting and conducting pre-clinical and clinical research to understand further the therapeutic effects of psilocybin and other consciousness-expanding medicines. Their focus is on alleviating depression in people whose current medical treatments fall short in offering relief and a better quality of life.

Usona has manufactured pharmaceutical-grade psilocybin and is currently conducting the necessary comprehensive pre-clinical toxicology work for prescription medication, enabling Ceruvia Lifesciences’ FDA clinical trials.

Usona Institute Logo
Heffter Research Institute logo

The Heffter Research Institute promotes the highest-quality scientific research with classic hallucinogens and related compounds (sometimes called psychedelics) to better understand how the mind improves the human condition and alleviates suffering.

Ceruvia Lifesciences seeks to take academic research Heffter has been instrumental in developing at elite universities and pivot it into prescription medication development trials required by FDA.

New York University (NYU), one of the nation’s premier academic medical centers, has newly created the NYU Langone Center for Psychedelic Medicine, which conducts trials for Ceruvia Lifesciences focusing on substance abuse disorder research.

Clusterbusters logo

Clusterbusters is a patient advocacy group that supports research for better headache disorders treatments while advocating to improve the lives of those struggling with cluster headaches. For the past ten years, their advocacy has been an essential tool for Ceruvia Lifesciences programs.

Ceruvia Lifesciences

Transformational Medicines for Neurological & Psychiatric Disorders